We are live on
!
Find out more
IAM
Innovis Asset Management Portfolio holdings
AUM
$260M
Turnover
30.65%
1-Year Est. Return
28.13%
This Fund
S&P 500
This Quarter
Est. Return
+10.77%
1 Year Est. Return
+28.13%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$271M
AUM Growth
+$24.2M
(+9.8%)
Cap. Flow
+$3.94M
Cap. Flow
% of AUM
1.45%
Top 10 Holdings %
Top 10 Hldgs %
35%
Holding
186
New
25
Increased
37
Reduced
82
Closed
24
Avg Time Held
0.4
years
Top 10 Avg Time Held
0.2
years
Top 20 Avg Time Held
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$4.52M |
| 2 |
Rockwell Automation
ROK
|
+$4.16M |
| 3 |
Newmont
NEM
|
+$3.45M |
| 4 |
Emerson Electric
EMR
|
+$3.41M |
| 5 |
Microsoft
MSFT
|
+$2.94M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$5.32M |
| 2 |
Freeport-McMoran
FCX
|
+$3.32M |
| 3 |
Corteva
CTVA
|
+$3.26M |
| 4 |
Devon Energy
DVN
|
+$3.24M |
| 5 |
UnitedHealth
UNH
|
+$2.68M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.6% |
| 2 | Healthcare | 22.77% |
| 3 | Financials | 8.72% |
| 4 | Energy | 6.58% |
| 5 | Consumer Staples | 6.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Apple
AAPL
$4.99T
| $21.9M | 8.1% |
113,131
-3,375
| -3% | -$588K |
2022 Q4
2 quarters
|
|
2
NVIDIA
NVDA
$5.25T
| $9.97M | 3.68% |
235,730
-3,610
| -2% | -$120K |
2022 Q4
2 quarters
|
|
3
Intuitive Surgical
ISRG
$151B
| $8.52M | 3.15% |
24,916
-422
| -2% | -$128K |
2022 Q4
2 quarters
|
|
4
Merck
MRK
$358B
| $8.45M | 3.12% |
73,233
+17,377
| +31% | +$1.97M |
2022 Q4
2 quarters
|
|
|
5
Newmont
NEM
$122B
| $8.02M | 2.96% |
188,110
+76,052
| +68% | +$3.45M |
2023 Q1
1 quarter
|
|
6
Vertex Pharmaceuticals
VRTX
$129B
| $7.93M | 2.93% |
22,539
+3,969
| +21% | +$1.34M |
2022 Q4
2 quarters
|
|
7
Palo Alto Networks
PANW
$303B
| $7.72M | 2.85% |
60,418
-164
| -0.3% | -$17.1K |
2022 Q4
2 quarters
|
|
8
DELISTED
Hess
HES
| $7.62M | 2.81% |
56,040
-170
| -0.3% | -$23.3K |
2022 Q4
2 quarters
|
|
9
Everpure Inc
P
$44.5B
| $7.34M | 2.71% |
199,371
+380
| +0.2% | +$10.8K |
2022 Q4
2 quarters
|
|
10
Oracle
ORCL
$408B
| $7.25M | 2.68% |
60,899
-19,938
| -25% | -$2.06M |
2022 Q4
2 quarters
|
|
11
Costco
COST
$433B
| $7.22M | 2.67% |
13,411
-237
| -2% | -$120K |
2022 Q4
2 quarters
|
|
12
Cboe Global Markets
CBOE
$32.2B
| $7.04M | 2.6% |
50,991
-192
| -0.4% | -$26.2K |
2022 Q4
2 quarters
|
|
13
Alphabet (Google) Class A
GOOGL
$4.27T
| $6.29M | 2.32% |
52,526
-35
| -0.1% | -$4.03K |
2022 Q4
2 quarters
|
|
|
14
Emerson Electric
EMR
$90.4B
| $6.02M | 2.22% |
66,604
+40,539
| +156% | +$3.41M |
2023 Q1
1 quarter
|
|
15
Enphase Energy
ENPH
$4.07B
| $5.93M | 2.19% |
35,398
+544
| +2% | +$97.2K |
2022 Q4
2 quarters
|
|
16
Chevron
CVX
$430B
| $5.83M | 2.15% |
37,048
-306
| -0.8% | -$49.1K |
2022 Q4
2 quarters
|
|
17
Thermo Fisher Scientific
TMO
$258B
| $5.74M | 2.12% |
11,008
+542
| +5% | +$292K |
2022 Q4
2 quarters
|
|
18
Boston Scientific
BSX
$64B
| $5.74M | 2.12% |
106,045
+30,340
| +40% | +$1.58M |
2022 Q4
2 quarters
|
|
|
19
UnitedHealth
UNH
$365B
| $5.57M | 2.06% |
11,595
-5,483
| -32% | -$2.68M |
2022 Q4
2 quarters
|
|
20
Visa
V
$750B
| $5.48M | 2.02% |
23,071
| – | – |
2022 Q4
2 quarters
|
|
21
Advanced Micro Devices
AMD
$918B
| $4.96M | 1.83% |
43,576
+14,934
| +52% | +$1.55M |
2022 Q4
2 quarters
|
|
|
22
DexCom
DXCM
$33.1B
| $4.8M | 1.77% |
+37,345
| New | +$4.52M |
2023 Q2
0 quarters
|
|
|
23
Rockwell Automation
ROK
$46.9B
| $4.74M | 1.75% |
+14,393
| New | +$4.16M |
2023 Q2
0 quarters
|
|
24
Berkshire Hathaway Class B
BRK.B
$1.13T
| $4.65M | 1.72% |
13,643
-4
| -0% | -$1.3K |
2022 Q4
2 quarters
|
|
|
25
Microsoft
MSFT
$4.01T
| $4.47M | 1.65% |
13,133
+9,374
| +249% | +$2.94M |
2022 Q4
2 quarters
|
|
Similar funds
RCGI
RBGI
AEPLI
PWM
T
SC
CA
W
Innovis Asset Management's Q2 2023 Portfolio in Review
As of Q2 2023, Innovis Asset Management held 186 positions worth $271M, up 9.8% from $247M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Innovis Asset Management's Q2 2023 filing shows 25 new, 37 increased, 82 reduced and 24 closed positions. Its largest new stake was DexCom: 37,345 shares worth $4.8M. The largest sale was Pfizer, an estimated $5.32M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 29% a quarter earlier, followed by Healthcare and Financials.
- Innovis Asset Management's largest Q2 2023 buy was DexCom: 37,345 shares worth $4.8M.
- Innovis Asset Management added most to Newmont in Q2 2023, an estimated $3.45M increase.
- Innovis Asset Management's biggest Q2 2023 reduction was Pfizer, cutting an estimated $5.32M.
- Innovis Asset Management fully exited Freeport-McMoran in Q2 2023, selling an estimated $3.32M.
- Innovis Asset Management's ten largest holdings make up 35% of its $271M portfolio in Q2 2023.
- Innovis Asset Management opened 25 new positions and closed 24 in Q2 2023.
- Innovis Asset Management's portfolio value rose 9.8% quarter-over-quarter to $271M.
Based on Innovis Asset Management's 13F filing for Q2 2023, filed 3 Aug 2023.